Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immune Pharmaceuticals Inc. (NASDAQ: IMNP).

Full DD Report for IMNP

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMNP)

Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
- Results from all subjects confirm excellent safety and tolerability and a large benefit across a variety of efficacy measures despite aggressive prednisone tapering - - Positive data support Company’s plans to commence pivotal registration study in 2019 - ENGLEWOOD CLI...
Source: GlobeNewswire
Date: May, 15 2018 09:00
Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc.
ENGLEWOOD CLIFFS, New Jersey, May 07, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, ...
Source: GlobeNewswire
Date: May, 07 2018 08:30
Market Trends Toward New Normal in The AES, Immune Pharmaceuticals, Hercules Capital, Zendesk, Chevron, and Cornerstone OnDemand - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The AES Corporation (NYSE:AES), Immune Pharmaceuticals Inc. (NASDAQ:IMNP),...
Source: GlobeNewswire
Date: May, 07 2018 08:25
Wired News - Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc
Stock Monitor: Immune Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free research report on Johnson & Johnson (NYSE: JNJ ) ("J&J"). If you want access to this report all you need to do is sign up now by clic...
Source: ACCESSWIRE IA
Date: April, 10 2018 07:40
Immune Pharmaceuticals reports FY results
Immune Pharmaceuticals (NASDAQ: IMNP ): FY EPS of -$2.11 More news on: Immune Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 02 2018 17:42
Immune Pharmaceuticals Announces 2017 Financial Results
ENGLEWOOD CLIFFS, NJ --(Marketwired - April 02, 2018) - Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune" or the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial resul...
Source: Marketwired
Date: April, 02 2018 17:20
Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium
ENGLEWOOD CLIFFS, NJ --(Marketwired - March 12, 2018) - Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune" or the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today the acceptance of ...
Source: Marketwired
Date: March, 12 2018 08:00
Research Report Identifies CarGurus, Peabody Energy, Brighthouse Financial, CPI Card Group, Alcoa, and Immune Pharmaceuticals with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CarGurus, Inc. (NASDAQ:CARG), Peabody Energy Corporation (NYSE:BTU), Bri...
Source: GlobeNewswire
Date: March, 05 2018 08:15
Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders
ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / February 27, 2018 / Immune Pharmaceuticals, Inc. ( NASDAQ; IMNP ) ("Immune" or the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal ...
Source: ACCESSWIRE
Date: February, 27 2018 08:00
Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update
- 5 of 6 Proposals Pass with Shareholder Approval - Meeting Adjourned Solely with Respect to Proposal 4 - Ratification of the Reverse Stock Split - Company Outlines Key Corporate and Clinical Milestones for 2018 ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / February 20, 2018 / Immune Pharmac...
Source: ACCESSWIRE
Date: February, 20 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.1350.1350.1450.135261,148
2018-08-160.1410.150.1540.137215,850
2018-08-150.130.1410.15550.13214,858
2018-08-140.1420.13120.16750.13593,530
2018-08-130.16250.15010.170.1501262,154

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-25175,325336,96652.0305Short
2018-07-2427,68373,03437.9043Short
2018-07-2327,714180,87315.3224Cover
2018-07-206,49140,98415.8379Cover
2018-07-1948,191347,69713.8601Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMNP.


About Immune Pharmaceuticals Inc. (NASDAQ: IMNP)

Logo for Immune Pharmaceuticals Inc. (NASDAQ: IMNP)

Immune Pharmaceuticals Inc. is focused on developing the next generation of monoclonal antibodies to address significant unmet medical needs in the treatment of cancer and inflammatory diseases. Our goal is to improve patients lives through targeted medicine.

 

 

 

Current Management

  • Daniel G. Teper / CEO
  • Sarit Steinberg / General Counsel, VP, Ops.
  • Anna Baran / Admin. Officer
  • Gad Berdugo /
  • Cameron Durrant /
  • Rene Lerer /
  • David Sidransky /
  • Ana Stancic /

Current Share Structure

  • Market Cap: $11,781,230 - 03/21/2018
  • Authorized: 225,000,000 - 03/01/2018
  • Issue and Outstanding: 32,277,343 - 03/01/2018

 


Recent Filings from (NASDAQ: IMNP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018

 

 


Daily Technical Chart for (NASDAQ: IMNP)

Daily Technical Chart for (NASDAQ: IMNP)


Stay tuned for daily updates and more on (NASDAQ: IMNP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IMNP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMNP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of IMNP and does not buy, sell, or trade any shares of IMNP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/